文献速递青光眼

10-2视野检查在青光眼进展检测中的价值

Value of 10-2 Visual Field Testing for Detecting Progression in Patients with Glaucoma.
PubMed 文献 · Ophthalmology · 2026-07-06

这项前瞻性纵向研究纳入96例早期视野缺损的开角型青光眼患者和56名健康参与者,每4个月进行24-2和10-2视野检查。结果显示,在全局和象限分析中,10-2并未比24-2提供更多信息;但在点对点分析中,当斜率截断值≤-1.25 dB/年时,10-2的AUC显著更高,支持对基线中心视野选择性更差且进展风险高的患者使用10-2随访。

要点

  • 全局和象限MD斜率分析中,10-2与24-2检测青光眼进展的AUC无显著差异。
  • 点对点TD斜率截断值≤-1.25 dB/年时,10-2的AUC显著高于24-2。
  • 仅10-2显示进展且斜率更陡的患者,其10-2基线MD更差,而24-2基线MD无此表现。

核心结论

  • 对于全局和象限分析,10-2视野检查相比24-2并未提供更多关于中心视野的信息。
  • 点对点分析支持对基线中心视野选择性更差且进展风险高的患者使用10-2随访。

研究设计与样本

  • 前瞻性纵向研究,纳入96例早期视野缺损的开角型青光眼患者和56名健康参与者,每只眼纳入分析。
  • 每4个月进行24-2和10-2视野检查,仅纳入≥5对检查者;分析24-2中央12个测试位点以匹配10-2区域。
  • 计算全局和象限平均偏差(MD)斜率及点对点总偏差(TD)斜率,采用基于点对点TD斜率截断值的进展标准。

主要发现

  • 青光眼患者中位随访4.69年、13对检查;健康参与者中位随访4.49年、11对检查。
  • 全局MD斜率AUC在两种检查间无显著差异(P=0.25),象限MD斜率AUC亦无显著差异(P>0.11)。
  • 全局MD斜率在90%特异性下,两种检查均判为进展的重叠比例为53%,象限MD斜率重叠更少。
  • 点对点斜率截断值>-1.25 dB/年时AUC无差异,≤-1.25 dB/年时10-2的AUC显著更高。
  • 仅10-2显示进展且点对点斜率截断值更陡的患者,其10-2基线MD更差,而24-2基线MD无此差异。

关键数值与推荐

  • 全局MD斜率在90%特异性下,两种检查判为进展的重叠比例为53%。
  • 点对点TD斜率截断值≤-1.25 dB/年时,10-2检测进展的AUC显著高于24-2。

临床怎么用

  • 全局和象限分析中,10-2未显示优于24-2,常规随访可仍以24-2为主。
  • 对基线中心视野选择性更差且进展风险高的患者,可考虑使用10-2进行点对点斜率分析随访。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the value of the 10-2 test of the Humphrey Field Analyzer (Carl Zeiss Meditec) in detecting visual field (VF) progression in early glaucoma. DESIGN: Prospective longitudinal study. PARTICIPANTS: Patients with open-angle glaucoma and healthy participants. METHODS: Participants were examined with the 24-2 and 10-2 tests every 4 months. Only those with 5 pairs of tests or more were included. To analyze the same area as the 10-2, only the central 12 test locations of the 24-2 test were included, from which global and quadrant mean deviation (MD) slopes and pointwise total deviation (TD) slopes were computed. A range of criteria for progression based on pointwise TD slope cutoffs was used. MAIN OUTCOME MEASURES: Measures included the area under the receiver operating characteristic curve (AUC) separating patients with glaucoma from healthy participants for global, sectoral, and pointwise analyses and overlap in the proportion of patients identified by the 2 tests at matched specificity. RESULTS: One eye each from 96 patients with glaucoma with early visual field damage and 56 healthy participants was included in the analysis. The participants were followed up for a median of 4.69 and 4.49 years with 13 and 11 pairs of tests, respectively. The AUCs of the MD slopes for the 2 tests were not significantly different for global (P = 0.25) or quadrant (P > 0.11) analysis. At 90% specificity for global MD slope, the overlap in patients classified as progressing with both tests was 53%, whereas for quadrant MD slope, the overlap was less. The AUCs were not different for pointwise slope cutoffs of more than -1.25 dB/year, but were significantly higher for the 10-2 test when cutoffs were -1.25 dB/year or less. Patients showing progression with only the 10-2 test with steeper pointwise slope cutoffs showed worse baseline MD on the 10-2, but not 24-2, test. CONCLUSIONS: For global and sectoral analyses, little evidence showed that the 10-2 test provided additional information about central visual VF compared with the 24-2 test. Pointwise analyses support the use of the 10-2 test for following up patients with selectively worse central VF loss at baseline and who are at risk of faster progression. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Tomita R, Salh D, Dyachok OM, et al. Value of 10-2 Visual Field Testing for Detecting Progression in Patients with Glaucoma. Ophthalmology. 2026. PMID: 42409179. doi:10.1016/j.ophtha.2026.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。